# Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)

> **NCT03018730** · PHASE3 · COMPLETED · sponsor: **Protalix** · enrollment: 22 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **BIOLOGICAL:** PRX-102 (pegunigalsidase alfa)

## Key facts

- **NCT ID:** NCT03018730
- **Lead sponsor:** Protalix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-17
- **Primary completion:** 2019-12-17
- **Final completion:** 2020-01-09
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03018730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03018730, "Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03018730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*